<?xml version='1.0' encoding='utf-8'?>
<document id="31511257"><sentence text="Elucidation of N1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters."><entity charOffset="15-33" id="DDI-PubMed.31511257.s1.e0" text="N1-methyladenosine" /></sentence><sentence text="Endogenous substrates are emerging biomarkers for drug transporters, which serve as surrogate probes in drug-drug interaction (DDI) studies" /><sentence text=" In this study, the results of metabolome analysis using wild-type and Oct1/2 double knockout mice suggested that N1-methyladenosine (m1A) was a novel organic cation transporter (OCT) 2 substrate"><entity charOffset="114-132" id="DDI-PubMed.31511257.s3.e0" text="N1-methyladenosine" /></sentence><sentence text=" An in vitro transport study revealed that m1A is a substrate of mouse Oct1, Oct2, Mate1, human OCT1, OCT2, and multidrug and toxin exclusion protein (MATE) 2-K, but not human MATE1" /><sentence text=" Urinary excretion accounted for 77% of the systemic elimination of m1A in mice" /><sentence text=" The renal clearance (46" /><sentence text="9 ± 4" /><sentence text="9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16"><entity charOffset="151-164" id="DDI-PubMed.31511257.s8.e0" text="pyrimethamine" /></sentence><sentence text="6 ± 2" /><sentence text="6 and 24" /><sentence text="3 ± 0" /><sentence text="6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations" /><sentence text=" In vivo inhibition of OCT2/MATE2-K by a single dose of 7-[(3R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid in cynomolgus monkeys resulted in the elevation of the area under the curve of m1A (1"><entity charOffset="56-177" id="DDI-PubMed.31511257.s13.e0" text="7-[(3R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid" /></sentence><sentence text="72-fold) as well as metformin (2"><entity charOffset="20-29" id="DDI-PubMed.31511257.s14.e0" text="metformin" /></sentence><sentence text="18-fold)" /><sentence text=" The plasma m1A concentration profile showed low diurnal and interindividual variation in healthy volunteers" /><sentence text=" The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance"><entity charOffset="185-195" id="DDI-PubMed.31511257.s17.e0" text="creatinine" /></sentence><sentence text=" The renal clearances of m1A and creatinine were 31% and 17% smaller in older than in younger volunteers"><entity charOffset="33-43" id="DDI-PubMed.31511257.s18.e0" text="creatinine" /></sentence><sentence text=" Thus, m1A could be a surrogate probe for the evaluation of DDIs involving OCT2/MATE2-K" /><sentence text=" SIGNIFICANCE STATEMENT: Endogenous substrates can serve as surrogate probes for clinical drug-drug interaction studies involving drug transporters or enzymes" /><sentence text=" In this study, m1A was found to be a novel substrate of renal cationic drug transporters OCT2 and MATE2-K" /><sentence text=" N1-methyladenosine was revealed to have some advantages compared to other OCT2/MATE substrates (creatinine and N1-methylnicotinamide)"><entity charOffset="1-19" id="DDI-PubMed.31511257.s22.e0" text="N1-methyladenosine" /><entity charOffset="97-107" id="DDI-PubMed.31511257.s22.e1" text="creatinine" /><entity charOffset="112-133" id="DDI-PubMed.31511257.s22.e2" text="N1-methylnicotinamide" /><pair ddi="false" e1="DDI-PubMed.31511257.s22.e0" e2="DDI-PubMed.31511257.s22.e0" /><pair ddi="false" e1="DDI-PubMed.31511257.s22.e0" e2="DDI-PubMed.31511257.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31511257.s22.e0" e2="DDI-PubMed.31511257.s22.e2" /><pair ddi="false" e1="DDI-PubMed.31511257.s22.e1" e2="DDI-PubMed.31511257.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31511257.s22.e1" e2="DDI-PubMed.31511257.s22.e2" /></sentence><sentence text=" The genetic or chemical impairment of OCT2 or MATE2-K caused a significant increase in the plasma m1A concentration in mice and cynomolgus monkeys due to the high contribution of tubular secretion to the net elimination of m1A" /><sentence text=" The plasma m1A concentration profile showed low diurnal and interindividual variation in healthy volunteers" /><sentence text=" Thus, m1A could be a better biomarker of variations in OCT2/MATE2-K activity caused by inhibitory drugs" /><sentence text="" /></document>